Daniel Associates

Regenerative Medicine Market by Type [Cell-Based Immunotherapy & Cell Therapy (Allogeneic & Autologous Products), Tissue Engineering, Gene Therapy], Applications (Wounds & Dermal, Musculoskeletal, Oncology), Region – Global Forecast to 2024

  • The Regenerative Medicine market was valued at USD XX Billion in 2018 and is estimated to reach USD XX Billion by 2024, at a CAGR of XX% during the forecast period. The base year used for this study is 2018, and the forecast period considered is between 2019 and 2024.

    The objectives of the study are as follows:

    • To define, describe, and forecast the Regenerative Medicine market segmented on the basis of by Type [Cell-Based Immunotherapy & Cell Therapy (Allogeneic & Autologous Products), Tissue Engineering, Gene Therapy], Applications (Wounds & Dermal, Musculoskeletal, Oncology), Region
    • To forecast the market size in terms of value for various segments with respect to four main regions: North America, Europe, APAC, and RoW
    • To provide detailed information regarding the major factors influencing the growth of the Regenerative Medicine market (drivers, restraints, opportunities, and industry-specific challenges)
    • To provide a detailed overview of the value chain in the Regenerative Medicine market and analyze the market trends with Porter’s five forces analysis
    • To analyze the opportunities in the market for various stakeholders by identifying the high-growth segments of the Regenerative Medicine market
    • To strategically profile the key players and comprehensively analyze their market position in terms of ranking and core competencies, along with detailing the competitive landscape for the market leaders
    • To analyze competitive developments such as new product launches and developments; agreements and contracts; mergers and acquisitions; and expansions in the global Regenerative Medicine market

    The years considered for the study are:

    Base Year – 2018         Estimated Year – 2019         Forecast Period – 2024

    For company profiles in the report, 2018 has been considered as the base year. In certain cases, wherein information is unavailable for the base year, the years prior to it have been considered.

    Scope of the Report:

    Regenerative Medicine Market, by Type

    Cell-Based Immunotherapy & Cell Therapy Products

    Allogeneic Products

    Autologous Products

    Gene Therapy Products

    Tissue-Engineered Products

    Regenerative Medicine, by Application

    Musculoskeletal Disorders

    Wound Care

    Oncology

    Ocular Disorders

    Diabetes

    Regenerative Medicine market, by Region

    North America

    Europe

    Asia Pacific

    Rest of the World

  • Table of Contents

    1 Introduction

    2 Research Methodologies

    3 Executive Summaries

    4 Premium Insights
        4.1 Regenerative Medicine: Market Overview
        4.2 Regenerative Medicine Market, By Type
        4.3 Regenerative Medicine Market, By Application

        4.4 Regenerative Medicine Market, By Region

    5 Market Overview
        5.1 Introduction
        5.2 Market Segmentation
        5.3 Market Dynamics
               5.3.1 Drivers
               5.3.2 Restraints
               5.3.3 Opportunities

    6 Regenerative Medicine Market, By Type
        6.1 Introduction
        6.2 Cell-Based Immunotherapy & Cell Therapy Products
               6.2.1 Allogeneic Products
               6.2.2 Autologous Products
        6.3 Tissue-Engineered Products
        6.4 Gene Therapy Products

    7 Regenerative Medicine Market, By Application
        7.1 Introduction
        7.2 Musculoskeletal Disorders
        7.3 Wound Care
        7.4 Oncology
        7.5 Ocular Disorders
        7.6 Diabetes
        7.7 Other Applications

    8 Regenerative Medicine Market, By Region
        8.1 Introduction
        8.2 North America
        8.3 Europe
        8.4 Asia Pacific
        8.5 Rest of the World

    9 Competitive Landscapes

    10 Company Profiles
         (Business Overview, Products & Services, Financials, Key Developments)*
         10.1 Novartis AG
         10.2 Vericel
         10.3 Integra Lifesciences
         10.4 Mimedx Group
         10.5 Stryker
         10.6 Wright Medical
         10.7 Spark Therapeutics
         10.8 Osiris Therapeutics
         10.9 Kite Pharma (Subsidiary of Gilead Sciences)
         10.10 Organogenesis

    *Details Might Not Be Captured in Case of Unlisted Companies.



  • Select User License